Evidence map›Paper›PMID 35018221›Full record

ReviewNew microbes and new infections2022

A systematic review on SARS-CoV-2 remission: an emerging challenge for its management, treatment, immunization strategies, and post-treatment guidelines.

R Joshi, R Singla, A Mishra, M Kumar, R S Singh, A Singh, S Bansal, A R Sharma, P Sarma, A Prakash and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in New microbes and new infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

R JoshiDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
R SinglaDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
A MishraDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
M KumarDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
R S SinghDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
A SinghDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
S BansalDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
A R SharmaDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
P SarmaDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
A PrakashDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
B MedhiDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Post Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 disease caused by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2) has posed as a major health concern for people all across the globe. Along with the increasing confirmed patients being readmitted with complaints for fever, cough, cold, the effective monitoring of 'relapse' of the SARS-CoV-2 virus in the previously discharged patients have become the next area of focus. However, availability of limited data on reactivation of SARS-CoV-2 makes the disease prognosis as well as the effective control of re-infection an immense challenge. Prompted by these challenges, we assessed the possibility of re-infection in discharged patients and the risk of the transmission, proficiency of RT-PCR results and approximate period required for the quarantine, and the real challenges for the development of vaccine. In the present review, the published literature on all the possible cases of re-infection from February to July were reported, thereby selected 142 studies from a hub of overall 669 studies after full text screening. The incomplete virus clearance, poor sensitivity of the present diagnostic testing, emergence of mutant strains, insufficient mucus collection from the throat swab etc., are some of the possible causes of re-infection. The new protocols for management of COVID-19 discharged patients should be revised in the guidelines.

Indexed as

COVID-19mutant strainsre-activationre-emissionre-infectionrelapse

Identifiers

PMID35018221
PMCPMC8739778
OpenAlexW4206485952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.